These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22382471)

  • 1. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years.
    Grace E
    J Antimicrob Chemother; 2012 Jun; 67(6):1305-10. PubMed ID: 22382471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection.
    Toma O; Suntrup P; Stefanescu A; London A; Mutch M; Kharasch E
    Anesth Analg; 2011 Oct; 113(4):730-7. PubMed ID: 21642605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vancomycin dosing in obese pediatric patients.
    Moffett BS; Kim S; Edwards MS
    Clin Pediatr (Phila); 2011 May; 50(5):442-6. PubMed ID: 21282257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A higher dose of vancomycin in continuous infusion is needed in critically ill patients.
    Jeurissen A; Sluyts I; Rutsaert R
    Int J Antimicrob Agents; 2011 Jan; 37(1):75-7. PubMed ID: 21074374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.
    Bearden DT; Rodvold KA
    Clin Pharmacokinet; 2000 May; 38(5):415-26. PubMed ID: 10843460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.
    Chaijamorn W; Jitsurong A; Wiwattanawongsa K; Wanakamanee U; Dandecha P
    Int J Antimicrob Agents; 2011 Aug; 38(2):152-6. PubMed ID: 21636256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin pharmacokinetics in patients with severe burn injuries.
    Dolton M; Xu H; Cheong E; Maitz P; Kennedy P; Gottlieb T; Buono E; McLachlan AJ
    Burns; 2010 Jun; 36(4):469-76. PubMed ID: 19875238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.
    Jarkowski A; Forrest A; Sweeney RP; Tan W; Segal BH; Almyroudis N; Wang ES; Wetzler M
    J Oncol Pharm Pract; 2012 Mar; 18(1):91-6. PubMed ID: 21521799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency.
    Pai MP; Mercier RC; Allen SE
    Ann Pharmacother; 2006 Mar; 40(3):553-8. PubMed ID: 16507618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias.
    Pai MP; Hong J; Krop L
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin Dosing in Obese Patients: Special Considerations and Novel Dosing Strategies.
    Durand C; Bylo M; Howard B; Belliveau P
    Ann Pharmacother; 2018 Jun; 52(6):580-590. PubMed ID: 29262697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered gentamicin serum concentrations in obese pediatric patients.
    Choi JJ; Moffett BS; McDade EJ; Palazzi DL
    Pediatr Infect Dis J; 2011 Apr; 30(4):347-9. PubMed ID: 20980932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
    Nunn MO; Corallo CE; Aubron C; Poole S; Dooley MJ; Cheng AC
    Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.
    DelDot ME; Lipman J; Tett SE
    Br J Clin Pharmacol; 2004 Sep; 58(3):259-68. PubMed ID: 15327585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.
    Hochart C; Berthon C; Corm S; Gay J; Cliquennois M; Tricot S; Alfandari S
    Med Mal Infect; 2011 Dec; 41(12):652-6. PubMed ID: 22056376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial dosing considerations in obese adult patients.
    Pai MP; Bearden DT
    Pharmacotherapy; 2007 Aug; 27(8):1081-91. PubMed ID: 17655508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
    Yang RH; Rong XZ; Hua R; Zhang T
    Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetic and pharmacodynamic properties of vancomycin.
    Rybak MJ
    Clin Infect Dis; 2006 Jan; 42 Suppl 1():S35-9. PubMed ID: 16323118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery.
    Barbour A; Schmidt S; Rout WR; Ben-David K; Burkhardt O; Derendorf H
    Int J Antimicrob Agents; 2009 Sep; 34(3):231-5. PubMed ID: 19411164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.